[In which pregnancy trimester is therapy with beta-mimetics of value? Beta receptor density in the course of pregnancy?].
L
L
Spätling
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D009215:Myometrium / Q000187:drug effects* / Q000503:physiopathology; D007752:Obstetric Labor, Premature / Q000503:physiopathology / Q000517:prevention & control*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D011943:Receptors, Adrenergic, beta / Q000187:drug effects* / Q000502:physiology; D015145:Tocolysis / Q000379:methods*
D000318:Adrenergic beta-Agonists; D011943:Receptors, Adrenergic, beta
Ab welcher Schwangerschaftswoche ist eine Therapie mit Betamimetika sinnvoll? Betarezeptorendichte im Verlauf der Schwangerschaft?